T6141

IMD-0354 (IKK2 Inhibitor V) is an IKKβ inhibitor that blocks IκBα phosphorylation in the NF-κB pathway.

FAK-IN-8 (compound 5h), a FAK inhibitor with an IC50 of 5.32 μM, exhibits potent anti-proliferative activity, making it suitable for use in cancer research [1].

InhA-IN-4 (TU14) is a potent inhibitor of Mycobacterium tuberculosis InhA (enoyl ACP reductase), with potential anticancer and antiproliferative activities for studying Mycobacterium tuberculosis infections.

Anticancer agent 47 (compound 4j) exhibits potent anticancer properties, demonstrating antiproliferative activities, inducing apoptosis, and causing cell cycle arrest at the G0/G1 phase. Moreover, Anticancer agent 47 has shown significant in vivo antitumor activities [1].

Gü1303 is a highly potent and reversible inhibitor of Cathepsin K (CatK), with a Ki value of 0.91 nM for mature CatK (mCatK). This compound effectively suppresses the autocatalytic activation of the CatK zymogen [1].

Compound 5a, also known as DPP-4 inhibitor 3, is a powerful dipeptidyl peptidase IV (DPP-IV) inhibitor, demonstrating an IC50 value of 0.75 nM. It exhibits outstanding antioxidant and insulinotropic activity [1].

FLT3/ITD-IN-1 (Compound 1) is a highly potent inhibitor of FLT3 internal tandem duplications (FLT3-ITD) with IC50 values of 38.2 nM for FLT3 and 144.1 nM for FLT3-ITD, and shows exceptional antiproliferative activities against several acute myeloid leukemia cell lines [1].

Antileishmanial agent-9 (compound 16c) exhibits potent and selective activity against Leishmania donovani (L. donovani) with an IC50 value of 4.01 μM, while demonstrating relatively low cytotoxicity in L-6 cells with an IC50 value of 40.1 μM [1].

PPARγ agonist 7 (Compound 3a) is a highly potent and selective peroxisome proliferator-activated receptor gamma (PPARγ) agonist, which specifically stimulates adiponectin production in human bone marrow mesenchymal stem cells (hBM-MSCs), demonstrating an innovative full agonist profile with an EC50 value of 4.34 μM [1].

BuChE-IN-6 (compound 1b) is a highly effective and specific inhibitor of BuChE (butyrylcholinesterase), with IC50 values of 0.46 μM for eqBuChE and 0.51 μM for hBuChE. Additionally, it inhibits the self-aggregation of Aβ 42 [1].

CXCR4 antagonist 5 (compound 23), a potent CXCR4 antagonist, exhibits high inhibition efficacy against CXCR4 with an IC50 value of 8.8 nM. It effectively suppresses CXCL12-induced cytosolic calcium increase (IC50 = 0.02 nM) and hinders CXCR4/CXCL12-mediated chemotaxis. Moreover, Compound 23 demonstrates favorable physicochemical properties and in vitro safety profiles, exhibiting only marginal to moderate inhibition of CYP isozymes and hERG [1].